Stephen Ansell, MD, PhD, from the Mayo Clinic, Rochester, MN, USA, provides an overview concerning the immunotherapeutic opportunities in the treatment of mantle cell lymphoma (MCL). He explains that although there is little known regarding immune responses in lymphoma, there have been promising results from studies focused on treating MCL with bispecific T-cell engagers (BiTEs) and CAR T-cells. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.